for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

CymaBay Therapeutics Inc

CBAY.O

Latest Trade

3.56USD

Change

-0.22(-5.70%)

Volume

781,054

Today's Range

3.32

 - 

3.81

52 Week Range

3.32

 - 

7.77

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest News

BRIEF-D. E. Shaw Reports 5% Passive Stake In Cymabay Therapeutics

* D. E. SHAW & CO., L.P. REPORTS 5% PASSIVE STAKE IN CYMABAY THERAPEUTICS AS OF MAY 26 -SEC FILING Source text: (https://bit.ly/3eUbW11) Further company coverage:

BRIEF-CymaBay Reports First Quarter 2020 Financial Results

* CYMABAY REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Engine Capital LP Deliveres Letter To Cymabay Therapeutics Nominating Arnaud Ajdler, Robert Frankfurt And Nadav Kidron To Board

* ENGINE CAPITAL LP SAYS ON MARCH 13, DELIVERED LETTER TO CYMABAY THERAPEUTICS NOMINATING ARNAUD AJDLER, ROBERT FRANKFURT AND NADAV KIDRON TO BOARD Source : (http://bit.ly/3aPfaRm) Further company coverage:

BRIEF-Engine Capital LP Deliveres Letter To Cymabay Therapeutics Nominating Arnaud Ajdler, Robert Frankfurt And Nadav Kidron To Board

* ENGINE CAPITAL LP SAYS ON MARCH 13, DELIVERED LETTER TO CYMABAY THERAPEUTICS NOMINATING ARNAUD AJDLER, ROBERT FRANKFURT AND NADAV KIDRON TO BOARD Source : (http://bit.ly/3aPfaRm) Further company coverage:

BRIEF-Cymabay Says Engine Capital Management Nominated 3 Candidates To Stand For Election To Board

* CYMABAY THERAPEUTICS COMMENTS ON ENGINE CAPITAL DIRECTOR NOMINATIONS

BRIEF-Cymabay Reports Q4 Loss Per Share $0.43

* CYMABAY REPORTS FOURTH QUARTER AND FISCAL YEAR END 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

CymaBay Therapeutics scraps liver disease studies; shares plunge

CymaBay Therapeutics Inc said on Monday it was scrapping two mid-stage studies testing its experimental drug in patients with non-alcoholic steatohepatitis (NASH) and another liver disease after it observed "atypical" findings in one trial, sending shares down 76% in premarket...

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up